MetaCap

Legend Biotech (LEGN) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Legend Biotech (LEGN) over the past year, gaining 148.5% versus a loss of 45.9%. Over five years, XERS leads with a +682.0% price change compared with -71.8% for LEGN. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.96 billion), about 1.0 times the size, while Legend Biotech is growing revenue faster (+64.0% vs +43.7%).

On valuation, Legend Biotech trades at a lower forward P/E (28.9x vs 63.6x for Xeris Biopharma). Xeris Biopharma converts more of its revenue into profit, with a net margin of 0.2% versus -28.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LEGN-45.86%XERS+148.46%
+158%+51%-56%
Nov 21, 20251 yearNov 20, 2026
LEGN-72.40%XERS+647.58%
+684%+288%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LEGN versus XERS key metrics
MetricLEGNXERS
Share price$15.25$16.97
Market cap$2.96B$3.10B
1-day change-5.28%+2.11%
YTD return-29.85%+116.18%
1-year return-45.86%+148.46%
5-year return-71.83%+682.03%
Forward P/E28.8963.64
EPS (TTM)$-0.02$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03B$291.85M
Revenue growth (YoY)+64.04%+43.72%
Net income (latest FY)$-296.80M$554.00K
Gross margin61.41%85.41%
Operating margin-13.27%8.53%
Net margin-28.85%0.19%
52-week high$37.50$17.28
52-week low$15.15$5.25
Distance from 52-week high-59.33%-1.79%
Analyst consensusbuystrong_buy
Avg. price target upside+168.39%+1.89%
Average volume2.26M2.86M
Shares outstanding193.97M182.70M
Employees3,300435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed LEGN by 194.3 percentage points over the past year.
  • Xeris Biopharma is more profitable, keeping 0.2 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
  • Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +43.72%).

About Legend Biotech

LEGN stock →

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).

Health Care · Biotechnology: Pharmaceutical Preparations · 3,300 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

LEGN vs XERS FAQ

Which is bigger, Legend Biotech or Xeris Biopharma?

Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.96B for Legend Biotech (LEGN).

Which stock has performed better over the past year, LEGN or XERS?

XERS returned +148.46% over the past 12 months, compared with -45.86% for LEGN (price return, excluding dividends). Past performance does not predict future results.

Are Legend Biotech and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons